Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study

Comparative Risk of Serious Infections with Tumor Necrosis Factor-α Antagonists vs. Vedolizumab in Patients with Inflammatory Bowel Diseases

(2021) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease

(2021) Neeraj Narula et al.   Clinical Gastroenterology and Hepatology

Vedolizumab and Anti-TNFα Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

(2021) Brian Bressler et al.   Journal of Crohns & Colitis

Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study

(2021) Yanna Ko et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

(2021) Siddharth Singh et al.   GASTROENTEROLOGY

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

(2021) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor

(2021) Laurène Parrot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

(2021) Daniel C. Baumgart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

(2021) Siddharth Singh et al.   Lancet Gastroenterology & Hepatology

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment

(2020) Vince B. C. Biemans et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Propensity Score Weighted Comparison of Vedolizumab and Adalimumab in Crohn’s Disease

(2020) Fabio Salvatore Macaluso et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

(2020) Matthew Bohm et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease

(2020) Julien Kirchgesner et al.   Clinical Gastroenterology and Hepatology

Development and validation of a structured query language implementation of the Elixhauser comorbidity index

(2017) Richard H Epstein et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

pSCANNER: patient-centered Scalable National Network for Effectiveness Research

(2014) L. Ohno-Machado et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011

(2013) Christine Rungoe et al.   GUT

Improving Case Definition of Crohnʼs Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing

(2013) Ashwin N. Ananthakrishnan et al.   INFLAMMATORY BOWEL DISEASES

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

(2013) Ole Haagen Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization

(2009) Liyan Liu et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY